Lyme Disease

OspA Vaccine Safe, Immunogenic in Previous Lyme Patients

Published in Vaccine Weekly, December 11th, 1995

Lyme vaccine researchers now have one less thing to worry about: the OspA vaccine currently in Phase III clinical trials is safe and immunogenic in people with previous Lyme disease.

Caused by the tick-borne spirochete Borrelia burgdorferi, early manifestations of Lyme disease can include meningitis and carditis and late manifestations can include arthritis and neurologic symptoms. While antibiotic treatment usually cures the disease, one out of 10 patients develop arthritis that can persist for years after antibiotic therapy.

There is recent evidence (B. Lengl-Janssen et al., J Exp Med 1994;180(6):2069-78) that the pathogenesis of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (1995-12-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry